T lymphocytes targeting native receptors
Identifieur interne : 001D82 ( Main/Exploration ); précédent : 001D81; suivant : 001D83T lymphocytes targeting native receptors
Auteurs : Cliona M. Rooney [États-Unis] ; Ann M. Leen [États-Unis] ; Juan F. Vera [États-Unis] ; Helen E. Heslop [États-Unis]Source :
- Immunological Reviews [ 0105-2896 ] ; 2014-01.
Abstract
The adoptive transfer of T cells specific for native tumor antigens (TAs) is an increasingly popular cancer treatment option because of the ability of these cells to discriminate between normal and tumor tissues and the corresponding lack of short or long‐term toxicities. Infusions of antigen‐specific CD4+ and CD8+ T cells targeting viral antigens derived from Epstein–Barr virus (EBV) induce sustained complete tumor remissions in patients with highly immunogenic tumors such as post‐transplant lymphoproliferative disease, although resistance occurred when the infused T‐cell population had restricted antigen specificity. T cells specific for EBV antigens have also produced complete remissions of EBV‐positive nasopharyngeal carcinomas and lymphomas developing in immunocompetent individuals, even though in these patients tumor survival is dependent on their ability to evade T‐cell immunity. Adapting this strategy to non‐viral tumors is more challenging, as the target antigens expressed are less immunogenic and the tumors lack the potent danger signals that are characteristic of viruses. The goals of current studies are to define conditions that promote expansion of antigen‐specific T cells ex vivo and to ensure their in vivo persistence and survival by combining with maneuvers such as lymphodepletion, checkpoint inhibition, cytokine infusions, or genetic manipulations. More pragmatic goals are to streamline manufacturing to facilitate the transition of these therapies to late phase trials and to evaluate closely histocompatibility antigen (HLA)‐matched banked antigen‐specific T cells so that T‐cell therapies can be made more broadly available.
Url:
DOI: 10.1111/imr.12133
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002421
- to stream Istex, to step Curation: 002421
- to stream Istex, to step Checkpoint: 000165
- to stream Main, to step Merge: 001D97
- to stream Main, to step Curation: 001D82
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">T lymphocytes targeting native receptors</title><author><name sortKey="Rooney, Cliona M" sort="Rooney, Cliona M" uniqKey="Rooney C" first="Cliona M." last="Rooney">Cliona M. Rooney</name></author><author><name sortKey="Leen, Ann M" sort="Leen, Ann M" uniqKey="Leen A" first="Ann M." last="Leen">Ann M. Leen</name></author><author><name sortKey="Vera, Juan F" sort="Vera, Juan F" uniqKey="Vera J" first="Juan F." last="Vera">Juan F. Vera</name></author><author><name sortKey="Heslop, Helen E" sort="Heslop, Helen E" uniqKey="Heslop H" first="Helen E." last="Heslop">Helen E. Heslop</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E644182F8B062FA23B1364BE2C8977A194286730</idno><date when="2014" year="2014">2014</date><idno type="doi">10.1111/imr.12133</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-JCR01289-L/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002421</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002421</idno><idno type="wicri:Area/Istex/Curation">002421</idno><idno type="wicri:Area/Istex/Checkpoint">000165</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000165</idno><idno type="wicri:doubleKey">0105-2896:2014:Rooney C:t:lymphocytes:targeting</idno><idno type="wicri:Area/Main/Merge">001D97</idno><idno type="wicri:Area/Main/Curation">001D82</idno><idno type="wicri:Area/Main/Exploration">001D82</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">T lymphocytes targeting native receptors</title><author><name sortKey="Rooney, Cliona M" sort="Rooney, Cliona M" uniqKey="Rooney C" first="Cliona M." last="Rooney">Cliona M. Rooney</name><affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, TX, Houston</wicri:regionArea><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Leen, Ann M" sort="Leen, Ann M" uniqKey="Leen A" first="Ann M." last="Leen">Ann M. Leen</name><affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, TX, Houston</wicri:regionArea><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Vera, Juan F" sort="Vera, Juan F" uniqKey="Vera J" first="Juan F." last="Vera">Juan F. Vera</name><affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, TX, Houston</wicri:regionArea><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Heslop, Helen E" sort="Heslop, Helen E" uniqKey="Heslop H" first="Helen E." last="Heslop">Helen E. Heslop</name><affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, TX, Houston</wicri:regionArea><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Immunological Reviews</title><title level="j" type="sub">Adoptive Immunotherapy for Cancer</title><title level="j" type="alt">IMMUNOLOGICAL REVIEWS</title><idno type="ISSN">0105-2896</idno><idno type="eISSN">1600-065X</idno><imprint><biblScope unit="vol">257</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="39">39</biblScope><biblScope unit="page" to="55">55</biblScope><biblScope unit="page-count">17</biblScope><date type="published" when="2014-01">2014-01</date></imprint><idno type="ISSN">0105-2896</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0105-2896</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">The adoptive transfer of T cells specific for native tumor antigens (TAs) is an increasingly popular cancer treatment option because of the ability of these cells to discriminate between normal and tumor tissues and the corresponding lack of short or long‐term toxicities. Infusions of antigen‐specific CD4+ and CD8+ T cells targeting viral antigens derived from Epstein–Barr virus (EBV) induce sustained complete tumor remissions in patients with highly immunogenic tumors such as post‐transplant lymphoproliferative disease, although resistance occurred when the infused T‐cell population had restricted antigen specificity. T cells specific for EBV antigens have also produced complete remissions of EBV‐positive nasopharyngeal carcinomas and lymphomas developing in immunocompetent individuals, even though in these patients tumor survival is dependent on their ability to evade T‐cell immunity. Adapting this strategy to non‐viral tumors is more challenging, as the target antigens expressed are less immunogenic and the tumors lack the potent danger signals that are characteristic of viruses. The goals of current studies are to define conditions that promote expansion of antigen‐specific T cells ex vivo and to ensure their in vivo persistence and survival by combining with maneuvers such as lymphodepletion, checkpoint inhibition, cytokine infusions, or genetic manipulations. More pragmatic goals are to streamline manufacturing to facilitate the transition of these therapies to late phase trials and to evaluate closely histocompatibility antigen (HLA)‐matched banked antigen‐specific T cells so that T‐cell therapies can be made more broadly available.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region><settlement><li>Houston</li></settlement></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Rooney, Cliona M" sort="Rooney, Cliona M" uniqKey="Rooney C" first="Cliona M." last="Rooney">Cliona M. Rooney</name></region><name sortKey="Heslop, Helen E" sort="Heslop, Helen E" uniqKey="Heslop H" first="Helen E." last="Heslop">Helen E. Heslop</name><name sortKey="Heslop, Helen E" sort="Heslop, Helen E" uniqKey="Heslop H" first="Helen E." last="Heslop">Helen E. Heslop</name><name sortKey="Leen, Ann M" sort="Leen, Ann M" uniqKey="Leen A" first="Ann M." last="Leen">Ann M. Leen</name><name sortKey="Vera, Juan F" sort="Vera, Juan F" uniqKey="Vera J" first="Juan F." last="Vera">Juan F. Vera</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D82 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D82 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E644182F8B062FA23B1364BE2C8977A194286730
|texte= T lymphocytes targeting native receptors
}}
| This area was generated with Dilib version V0.6.33. |  |